US · RDHL · DRUG MANUFACTURERS - SPECIALTY & GENERIC
RedHill Biopharma Ltd. (RDHL) intrinsic value and stock valuation
$0.28as of 2026-11-21 · Mkt cap 1.9M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
RedHill Biopharma Ltd. DCF and intrinsic value
InvestorsCraft values RDHL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RDHL’s statements →
RedHill Biopharma Ltd. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $290K | $8.04M | $6.53M | $61.8M | $85.8M |
| Operating income | -$-7.91M | -$-14.61M | $12.6M | -$-42.84M | -$-81.14M |
| Net income | -$-430K | -$-8.27M | $23.9M | -$-71.67M | -$-97.74M |
| EPSd | -$-136.08K | -$-3.36M | $46M | -$-597.25M | -$-1.09B |
| Operating cash flow | -$-9.65M | -$-9.37M | -$-35.82M | -$-29.18M | -$-65.05M |
| Capital expenditure | -$-10K | -$-10K | -$-10K | -$-200K | -$-120K |
| Free cash flow | -$-9.66M | -$-9.38M | -$-35.83M | -$-29.38M | -$-65.16M |
| Total assets | $25.3M | $18M | $23.1M | $158.9M | $181.2M |
| Total debt | $1.07M | $360K | $1.17M | $122.7M | $87.8M |
| Net debt | -$-2.9M | -$-4.26M | -$-4.4M | $102.7M | $58.3M |
| Total equity | $4.27M | -$-4.68M | $2.07M | -$-48.4M | $8.88M |
| Cash and short-term investments | $3.97M | $4.62M | $6.36M | $20M | $38M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $290K | $8.04M | $6.53M | $61.8M | $85.8M |
| Cost of revenue | $0.00 | $3.19M | $3.46M | $33.3M | $49.4M |
| Gross profit | $290K | $4.85M | $3.07M | $28.5M | $36.4M |
| Research and development expenses | $2.02M | $1.59M | $3.53M | $7.28M | $29.5M |
| Selling, general and administrative expenses | $6.17M | $15.5M | $31M | $64M | $88M |
| Other expenses | $0.00 | $2.36M | -$-44.06M | $0.00 | $0.00 |
| Operating expenses | $8.2M | $19.5M | -$-9.56M | $71.3M | $117.5M |
| Cost and expenses | $8.2M | $22.7M | -$-6.1M | $104.6M | $166.9M |
| Interest income | $20K | $130K | $90K | $140K | $50K |
| Interest expense | $20K | $60K | $370K | $41.3M | $16.6M |
| Depreciation and amortization | $410K | $620K | $1.99M | $8.15M | $18.2M |
| Ebitda | -$-7.65M | -$-7.59M | $26.3M | -$-22.18M | -$-63.03M |
| Operating income | -$-7.91M | -$-14.61M | $12.6M | -$-42.84M | -$-81.14M |
| Total other income/expenses, net | -$-170K | $6.34M | $11.3M | -$-28.82M | -$-16.61M |
| Income before tax | -$-8.08M | -$-8.27M | $23.9M | -$-71.67M | -$-97.74M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-430K | -$-8.27M | $23.9M | -$-71.67M | -$-97.74M |
| Weighted average shares outstanding | $3.16M | $2.46M | $520K | $120K | $90K |
| Weighted average diluted shares outstanding | $3.16M | $2.46M | $520K | $120K | $90K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $3.97M | $4.62M | $6.36M | $20M | $38M |
| Net receivables | $2.48M | $3.57M | $3.29M | $37.9M | $32.5M |
| Inventory | $0.00 | $3.65M | $4.39M | $11M | $14.8M |
| Total current assets | $6.53M | $11.9M | $16.1M | $85.9M | $89.2M |
| Property, plant and equipment, net | $1.1M | $440K | $1.18M | $7.19M | $4.22M |
| Goodwill and intangible assets | $5.29M | $5.55M | $5.58M | $65.6M | $71.6M |
| Long-term investments | $12.1M | $150K | $150K | $150K | $16.2M |
| Total non-current assets | $18.8M | $6.13M | $6.91M | $73M | $92M |
| Total assets | $25.3M | $18M | $23.1M | $158.9M | $181.2M |
| Accounts payable | $6.42M | $7.86M | $3.28M | $4.23M | $11.7M |
| Short-term debt | $170K | $710K | $1.44M | $116.3M | $3.24M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $37.3M |
| Total current liabilities | $19.2M | $22.2M | $19.2M | $197.5M | $81.5M |
| Long-term debt | $900K | $0.00 | $460K | $6.44M | $86.2M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.86M | $500K | $1.74M | $9.82M | $90.8M |
| Capital lease obligations | $1.07M | $360K | $1.17M | $7.47M | $4.19M |
| Total liabilities | $21.1M | $22.7M | $21M | $207.3M | $172.3M |
| Common stock | $147.6M | $35M | $21.4M | $2.83M | $1.5M |
| Retained earnings | -$-413.75M | -$-414.8M | -$-407.74M | -$-433.86M | -$-367.87M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $4.27M | -$-4.68M | $2.07M | -$-48.4M | $8.88M |
| Total investments | $12.1M | $150K | $940K | $170K | $24.7M |
| Total debt | $1.07M | $360K | $1.17M | $122.7M | $87.8M |
| Net debt | -$-2.9M | -$-4.26M | -$-4.4M | $102.7M | $58.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-430K | -$-8.27M | $23.9M | -$-71.67M | -$-97.74M |
| Depreciation and amortization | $410K | $620K | $1.99M | $8.15M | $18.2M |
| Stock-based compensation | $460K | $670K | $1.65M | $5.67M | $10.2M |
| Change in working capital | -$-1.97M | $2.05M | -$-15.58M | $8.01M | -$-1.15M |
| Accounts receivable | $2.26M | $50K | $33.4M | -$-2.85M | -$-3.02M |
| Inventory | -$-380K | $740K | $2.38M | $3.8M | -$-8.29M |
| Accounts payable | -$-440K | -$-2.11M | -$-950K | -$-7.43M | $110K |
| Net cash provided by operating activities | -$-9.65M | -$-9.37M | -$-35.82M | -$-29.18M | -$-65.05M |
| Investments in property, plant and equipment | -$-10K | -$-10K | -$-10K | -$-200K | -$-120K |
| Acquisitions, net | $2M | $0.00 | $0.00 | $0.00 | $8.03M |
| Net cash used for investing activities | $1.69M | -$-10K | $0.00 | $8.3M | -$-8.14M |
| Common stock issued | $7.76M | $8.26M | $14M | $23.8M | $78.5M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $7.32M | $8.42M | $21.4M | $11.5M | $73.5M |
| Net change in cash | -$-650K | -$-950K | -$-14.4M | -$-9.51M | $180K |
| Cash at end of period | $3.97M | $4.62M | $5.57M | $20M | $29.5M |
| Operating cash flow | -$-9.65M | -$-9.37M | -$-35.82M | -$-29.18M | -$-65.05M |
| Capital expenditure | -$-10K | -$-10K | -$-10K | -$-200K | -$-120K |
| Free cash flow | -$-9.66M | -$-9.38M | -$-35.83M | -$-29.38M | -$-65.16M |
Line items
Line items
Line items
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
- CEO
- Dror Ben-Asher
- Employees
- 13
- Beta
- 4.97
Explore
Frequently asked questions
What is the intrinsic value of RedHill Biopharma Ltd. (RDHL)?
InvestorsCraft does not currently publish an intrinsic value for RDHL. How the IC value is calculated.
Is RDHL undervalued?
InvestorsCraft does not publish an undervaluation signal for RDHL at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.